Johnson & Johnson Partners to Empower Lung Cancer Patients

News Summary

Johnson & Johnson Innovative Medicine Asia Pacific has joined forces with regional patient advocacy group leaders to enhance shared decision-making in lung cancer care. This collaboration, highlighted at the ESMO Asia 2025 conference in Singapore, aims to promote a patient-centered approach and empower patients in their treatment journeys, featuring initiatives like ‘The 3rd Opinion’ campaign and the launch of the ‘J&J withMe’ online hub for resources.

Singapore

In a significant move to enhance patient empowerment and improve treatment outcomes, Johnson & Johnson Innovative Medicine Asia Pacific recently collaborated with patient advocacy group leaders from across the region to strengthen shared decision-making in lung cancer care. The pivotal discussions and announcements took place at the ESMO Asia 2025 conference in Singapore, emphasizing a patient-centered approach to complex treatment pathways. This initiative is a crucial component of the ongoing “The 3rd Opinion” campaign, which seeks to elevate the patient’s voice in their healthcare journey.

During a Patient Reception on December 6, 2025, twenty leaders representing seventeen patient advocacy groups from the Asia Pacific, Europe, and the United States converged to voice their strong support for enhancing shared decision-making practices. This was followed by the ESMO Asia 2025 Symposium on December 7, 2025, which specifically highlighted the vital role of healthcare professionals in guiding patients and their families through intricate treatment choices, particularly for EGFR-mutated non-small cell lung cancer (NSCLC). The announcement of the next phase of “The 3rd Opinion” campaign in Asia Pacific occurred around December 11, 2025.

Elevating the Patient Voice Through Collaborative Initiatives

The core of this collaborative effort is “The 3rd Opinion” campaign, a new term designed to spark a social movement that empowers lung cancer patients to actively participate in shaping their treatment plans. This collaborative approach ensures that treatment decisions are aligned with each patient’s personal goals, preferences, and unique circumstances, leading to more informed choices, increased patient satisfaction, and ultimately, better health outcomes.

Supporting this goal, Johnson & Johnson has also launched “J&J withMe,” an online hub dedicated to equipping lung cancer patients and their caregivers with essential resources. This portal offers tailored toolkits and conversation guides, preparing individuals for consultations and enabling them to make well-informed, personalized treatment decisions. Beyond digital tools, the company is co-driving specific initiatives within various markets in collaboration with local patient advocacy groups to foster greater patient empowerment across the Asia Pacific region.

Addressing Patient Satisfaction and Engagement

Recent patient surveys underscore the critical need for shared decision-making. Findings indicate that patients who were actively involved in shared decision-making processes were eleven times more likely to report higher satisfaction with their treatments. Furthermore, a significant ninety percent of lung cancer patients in Japan expressed a desire to play an active role in their treatment decisions. This data highlights a clear demand for more patient-centric care models.

Despite these preferences, studies in the Asia Pacific region reveal a gap: up to seventy-seven percent of patients often trust and rely on their physicians to make treatment decisions for them. This occurs even though sixty-nine percent of physicians encourage patients to engage in shared decision-making. This disparity emphasizes the need for initiatives like “The 3rd Opinion” to bridge the communication gap and empower patients to voice their preferences effectively.

The Urgent Need for Enhanced Lung Cancer Care in Asia Pacific

The urgency of strengthening shared decision-making is particularly pronounced in the Asia Pacific region, which bears a disproportionately high burden of lung cancer. In 2022, the region accounted for sixty percent of global lung cancer deaths, making it the deadliest cancer in the Asia Pacific. Projections suggest this trend will continue through 2050. Moreover, Asia is home to sixty-three percent of all lung cancer patients worldwide. The high prevalence of certain non-small cell lung cancer (NSCLC) mutations in Asia, such as EGFR mutations, makes the choice of first-line therapy absolutely critical, requiring a balance between clinical objectives and patient values.

Addressing Systemic Challenges

Comprehensive studies have identified significant systemic gaps in lung cancer care across the Asia Pacific. These include patients having suboptimal disease and treatment knowledge, limited engagement in shared decision-making, the enduring stigma associated with cancer, and inadequate psychosocial support. Many patients lack a full understanding of genetic mutations and often experience delays in diagnosis. Culturally, there has been a longstanding tendency for patients to defer to physicians, which underscores the importance of efforts to encourage patients to articulate their own opinions and goals for treatment.

To combat these challenges, Johnson & Johnson is pursuing a multi-pronged approach involving various stakeholders, including policymakers, oncologists, nurses, advocacy groups, caregivers, and patients. This commitment extends to developing transformative therapies targeting common and rare EGFR mutations and supporting broader policy work, such as the Asia Pacific Lung Cancer Policy Consensus. This consensus document, authored by ASPIRE for Lung Cancer and the Asia Pacific Coalition Against Lung Cancer (APCLC), provides region-specific recommendations to improve lung cancer care. By tailoring strategies to the unique epidemiological patterns, environmental risks, and varied healthcare infrastructures of the Asia Pacific, the initiative aims to translate global visions into practical local actions, ultimately improving outcomes and ensuring equitable care for all.

Frequently Asked Questions

What is the main goal of the collaboration between Johnson & Johnson and Asia Pacific patient advocacy groups?

The main goal is to strengthen shared decision-making in lung cancer care, empowering patients to play a more active role in their treatment decisions.

Where did the recent announcements and events related to this initiative take place?

The recent announcements and stakeholder engagements, including a Patient Reception and ESMO Asia 2025 Symposium, took place in Singapore.

What is “The 3rd Opinion” campaign?

“The 3rd Opinion” is a campaign designed to elevate the patient’s voice and spark a social movement that empowers lung cancer patients to confidently articulate their personal goals for treatment, fostering collaborative care.

What is “J&J withMe” and how does it help patients?

“J&J withMe” is an online hub launched by Johnson & Johnson that provides lung cancer patients and caregivers with tailored toolkits and conversation guides to prepare for consultations and make informed, personalized treatment decisions.

Why is shared decision-making particularly important in the Asia Pacific region for lung cancer?

The Asia Pacific region faces a disproportionately high burden of lung cancer, accounting for sixty percent of global lung cancer deaths and sixty-three percent of all lung cancer patients worldwide. There are also significant gaps in patient knowledge, limited shared decision-making, and cultural tendencies to defer to physicians.

What impact does shared decision-making have on patient satisfaction?

Patient surveys indicate that those engaged in shared decision-making were eleven times more likely to report higher satisfaction with their treatments.

Key Features of the Initiative

Deeper Dive: News & Info About This Topic

Care Management Solutions Market Projected to Surpass $43.80 Billion by 2032
Patient Advocates for Early Detection in Lung Cancer
The Role of Patient Advocacy in Cancer Research
Positive Outlook Fuels Cancer Advocacy
Johnson & Johnson Partners with Advocacy Leaders for Lung Cancer Care
St. Louis Couple Advocates for Lung Cancer Awareness and Early Detection